“Vaccines such as Pfizer have been shown to be less effective against new strains of the coronavirus, in some cases below 50 percent.

However, the effectiveness of the Spikogen vaccine has been higher than the permitted values in the World Health Organization guidelines,” Mohammad Reza Shanehsaz, head of the Food and Drug Administration, said.

“Currently, the predominant coronavirus in the country includes Delta, British, and Wuhan variants; the clinical study of the Spikogen is one of the few studies in the world to have been conducted entirely at the peak of the Delta variant.

At the third phase of the clinical study, the efficacy of the vaccine before the onset of symptomatic and mild cases of Covid-19 and in the prevalence of delta strain in the country is estimated at about 60 to 65 percent,” he noted.

The monthly production capacity of Spikogen is at least three million doses, according to the Sinogen pharmaceutical company.

The first phase of the study was performed on volunteer Australians and received the necessary approval, the second phase was administrated to 400 Iranians, which has had no serious side effects.

Vaccines against viruses can be divided into three main categories: live attenuated, inactivated/killed, and subunit vaccines. Recombinant protein subunit vaccines are composed of at least 1 type of viral antigen. These vaccines are significantly more secure than live attenuated and inactivated vaccines.

Mass vaccination against COVID-19 started on Iranian citizens with the Russian-made Sputnik V vaccine on February 9.

While Iran continues efforts to mass-produce local candidates, over 80 million doses of foreign vaccines have already been imported and others are expected soon.

Iran is also producing vaccines jointly with two countries of Cuba and Russia.

The post Spikogen vaccine licensed for emergency use appeared first on Iran News Daily.

This is subject to approval and obtaining a license from the Food and Drug Administration, which seems to be approved given the circumstances, he stated.

He estimated the monthly capacity of the Sinogen pharmaceutical company to produce the vaccine at three million doses.

Pointing to the safety level of Spikogen as 77 percent, he noted that the third phase of the clinical trial will probably end in late September, IRNA reported on Saturday.

About 2 weeks after the vaccine is injected into all third-phase volunteers, its effectiveness can be announced more accurately, he further said.

The first phase of the study was performed on volunteer Australians and received the necessary approval, the second phase was administrated to 400 Iranians, which has had no serious side effects, Tabarsi said.

Vaccines against viruses can be divided into three main categories: live attenuated, inactivated/killed, and subunit vaccines. Recombinant protein subunit vaccines are composed of at least 1 type of viral antigen. These vaccines are significantly more secure than live attenuated and inactivated vaccines.

Mass vaccination against COVID-19 started on Iranian citizens with the Russian-made Sputnik V vaccine on February 9.

While Iran continues efforts to mass-produce local candidates, over 18 million doses of foreign vaccines have already been imported and others are expected soon.

Iran is also producing vaccines jointly with two countries of Cuba and Russia.

Homegrown vaccines

Made by researchers at the Headquarters for Executing the Order of the Imam, COVIRAN BAREKAT was unveiled on December 29, 2020, and received the license for public use on June 14.

It proved effective against Indian strain, according to Hojjat Niki-Maleki, head of the information center of Headquarters for Executing the Order of the Imam.

Eleven countries from Asia and South America, and a European country have asked for importing COVIRAN vaccine, Hassan Jalili, the vaccine’s production manager, said in June.

According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.

Pastu Covac, developed jointly by the Pasteur Institute of Iran and Cuba’s Finlay Vaccine Institute, is another homegrown vaccine, which has received the emergency use license, after COVIRAN.

The post Spikogen to join COVID-19 vaccination rollout by October appeared first on Iran News Daily.

The first phase of the study was performed on volunteer Australians and received the necessary approval, the second phase was administrated to 400 Iranians, which has had no serious side effects, Payam Tabarsi, researcher of the vaccine study project said.

The second human testing showed good results, with 70 percent antibody, he stated, adding, the delta variant is now very strong and many vaccines have not been effective against the mutant.

Vaccines against viruses can be divided into three main categories: live attenuated, inactivated/killed, and subunit vaccines. Recombinant protein subunit vaccines are composed of at least 1 type of viral antigen. These vaccines are significantly more secure than live attenuated and inactivated vaccines.

Iran is also producing vaccines jointly with two countries of Cuba and Russia, which may also be released by September.

The Iranian-made Sputnik vaccine is undergoing the final testing phase, and Pastu Covac received the emergency use license.

Mass vaccination against COVID-19 started on Iranian citizens with the Russian-made Sputnik V vaccine on February 9.

While Iran continues efforts to mass-produce local candidates, over 13 million doses of foreign vaccines have already been imported and others are expected soon.

According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.

The post Spikogen vaccine enters third phase of clinical trial appeared first on Iran News Daily.